Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPIVACAINE HYDROCHLORIDE vs ALPHACAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bupivacaine hydrochloride is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the generation and propagation of action potentials and producing reversible local anesthesia.
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Local or regional anesthesia for surgical procedures,Dental anesthesia,Obstetric anesthesia (epidural),Postoperative pain management,Off-label: peripheral nerve blocks, sympathetic nerve blocks
Local anesthesia by infiltration or nerve block,Spinal anesthesia,Epidural anesthesia
0.25% to 0.5% solution infiltrated locally, up to 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000) per dose; maximum 400 mg per 24 hours. For epidural: 0.5% to 0.75% solution, 15-20 m L for surgical anesthesia.
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
Terminal elimination half-life: 2.7 hours (adults); prolonged in neonates (8.1 hours) and patients with hepatic impairment; clinical context: half-life increases with repeated dosing due to accumulation.
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
Primarily hepatic via conjugation with glucuronic acid; CYP3A4 and CYP1A2 involved in metabolism to pipecoloxylidine and desbutylbupivacaine.
Hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol.
Primarily hepatic metabolism (CYP3A4, CYP1A2, and amidases) to pipecoloxylidine and desbutylbupivacaine; less than 5% excreted unchanged in urine; negligible biliary/fecal excretion.
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
Approximately 95% bound to alpha-1-acid glycoprotein (AAG) and albumin; binding is concentration-dependent and decreases in acidosis.
90-95% bound to alpha-1-acid glycoprotein and albumin.
Vd: 0.73 L/kg (range 0.5-1.0 L/kg) in adults; reflects extensive tissue binding; lower in neonates (0.3-0.6 L/kg) due to reduced adipose tissue.
Vd 0.8-1.2 L/kg; extensive tissue distribution (liver, lungs, brain).
Not applicable for intravenous use; epidural: ~100% (systemic absorption from epidural space); peripheral nerve block: variable (systemic absorption depends on site and dose); oral: negligible (<5%) due to extensive first-pass metabolism.
Oral: 30-40% (first-pass metabolism); Intramuscular: 85-95%; Intravenous: 100%.
No specific dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: use with caution, reduce dose by 25% and monitor for toxicity. For GFR <10 m L/min: avoid or reduce dose by 50% with close monitoring.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation. Monitor for CNS toxicity.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: contraindicated or use minimal effective dose with extreme caution.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use alternative agent.
Infants and children: 0.25-0.5% solution, maximum 2 mg/kg (without epinephrine) or 3 mg/kg (with epinephrine), not to exceed 175 mg total.
Local infiltration: 0.5–2% solution, maximum 4.5 mg/kg (without epinephrine) or 7 mg/kg (with epinephrine). For nerve blocks: weight-based dosing, not to exceed adult maximum.
Elderly patients: reduce dose by 25-50% due to decreased clearance and increased sensitivity; consider lower concentrations and volumes; avoid rapid infusion.
Reduce total dose by 20–30% due to decreased clearance and increased sensitivity; monitor for prolonged effect and toxicity.
Risk of cardiac arrest and death following unintended intravenous injection or administration of high doses; resuscitation may be difficult and prolonged.
Not available.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Avoid for spinal anesthesia when high doses are needed due to neurotoxicity risk,Monitor for signs of CNS and cardiovascular toxicity,Use in pregnant women only if clearly needed (Category C)
Risk of systemic toxicity if absorbed into circulation,Hypersensitivity to ester-type anesthetics,Potential for methemoglobinemia with high doses,Use with caution in patients with impaired cardiac or hepatic function
Hypersensitivity to bupivacaine or other amide anesthetics,Severe hypotension (e.g., hypovolemic shock),Inflammation or sepsis at injection site,Paracervical block in obstetrics (associated with fetal bradycardia),Use for intravenous regional anesthesia (Bier block)
Hypersensitivity to ester-type anesthetics or para-aminobenzoic acid,Severe hypotension,Bleeding disorders (for spinal/epidural use),Infection at the injection site
No known food interactions. Grapefruit juice may affect hepatic metabolism via CYP3A4 inhibition, but clinical significance is minimal. Maintain normal diet.
No known food interactions. Avoid excessive grapefruit or grapefruit juice consumption due to potential CYP3A4 inhibition.
Bupivacaine is classified as FDA Pregnancy Category C. In first trimester, no well-controlled studies; animal studies have shown potential for fetal toxicity at high doses. Second and third trimesters: risk of fetal bradycardia and acidosis due to placental transfer. Epidural use may cause maternal hypotension reducing uteroplacental perfusion. Avoid paracervical block in pregnancy due to risk of fetal bradycardia.
Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in first trimester if possible.
Bupivacaine is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.30. It is considered compatible with breastfeeding; however, monitor infant for signs of local anesthetic toxicity such as drowsiness or irritability.
Excreted in breast milk in low amounts; M/P ratio not established. Consider risk-benefit; monitor infant for central nervous system depression.
Increased plasma volume and decreased plasma protein binding in pregnancy may require reduced doses to avoid toxicity. However, standard epidural doses often remain similar; dose adjustment should be based on clinical response and weight. Use lower doses for combined spinal-epidural. Maximum single epidural dose: 2.5 mg/kg (non-pregnant), but in pregnancy consider 2.0 mg/kg due to increased sensitivity.
No specific dose adjustments required; pharmacokinetics may be altered but clinical significance unclear.
Bupivacaine is a long-acting amide local anesthetic. Maximum single dose is 2.5 mg/kg (with epinephrine 3 mg/kg). Cardiotoxicity is greater than lidocaine; avoid intravascular injection. Use with caution in hepatic impairment. For labor analgesia, 0.0625-0.125% with fentanyl is common. Adding epinephrine prolongs duration and reduces peak plasma concentration.
Alphacaine Hydrochloride is an amide-type local anesthetic similar to lidocaine. Onset of action is 2-5 minutes with duration of 30-120 minutes depending on concentration and use of epinephrine. It is hepatically metabolized (CYP3A4) and renally excreted. Dose adjustment required in hepatic impairment. Risk of methemoglobinemia, especially in infants and patients on sulfonamides. Do not exceed maximum doses: 4.5 mg/kg plain, 7 mg/kg with epinephrine.
Report any numbness or tingling beyond expected area of anesthesia.,Seek immediate medical attention if you experience ringing in ears, metallic taste, dizziness, or seizures.,Inform your healthcare provider if you have liver disease or are taking antiarrhythmics.,Avoid driving or operating machinery until full sensation returns.,Do not apply heat or cold to the numb area to prevent burns or frostbite.
Avoid alcohol consumption for 24 hours after procedure.,Inform your doctor if you have liver disease, heart block, or history of methemoglobinemia.,Do not drive or operate machinery until effects wear off.,Report numbness, tingling, or twitching immediately.,For dental procedures: avoid eating until numbness resolves to prevent injury.
"The concurrent administration of nitrous oxide and bupivacaine may increase the risk of cardiovascular depression and arrhythmias due to synergistic cardiovascular depressant effects. Nitrous oxide can cause sympathetic nervous system activation and myocardial depression, while bupivacaine prolongs ventricular depolarization and increases the risk of reentrant arrhythmias, particularly at high doses. This combination may lead to hypotension, bradycardia, or more severe cardiac conduction abnormalities, especially in patients with preexisting cardiac disease."
"The coadministration of bupivacaine, a sodium channel blocker used for local anesthesia, with diclofenamide, a carbonic anhydrase inhibitor and diuretic, may lead to metabolic acidosis and altered electrolyte balance, thereby increasing the risk of bupivacaine-induced cardiotoxicity and central nervous system (CNS) toxicity. Diclofenamide can cause hypokalemia and hypocalcemia, which potentiate the sodium channel blocking effects of bupivacaine, resulting in arrhythmias, seizures, or other adverse effects. This interaction is clinically significant especially in patients with renal impairment or those on multiple electrolyte-altering medications."
"Oxymorphone, a potent mu-opioid receptor agonist, and bupivacaine, a local anesthetic that blocks sodium channels, both depress the central nervous system (CNS) and respiratory drive. Coadministration may lead to additive CNS and respiratory depression, increasing the risk of severe adverse effects such as hypotension, bradycardia, and respiratory arrest. Clinical outcomes include enhanced sedation, confusion, and possibly fatal respiratory compromise, especially in patients with compromised cardiovascular function or those receiving high doses of either agent."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPIVACAINE HYDROCHLORIDE vs ALPHACAINE HYDROCHLORIDE, answered by our medical review team.
BUPIVACAINE HYDROCHLORIDE is a Local Anesthetic that works by Bupivacaine hydrochloride is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the generation and propagation of action potentials and producing reversible local anesthesia.. ALPHACAINE HYDROCHLORIDE is a Local Anesthetic that works by Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPIVACAINE HYDROCHLORIDE and ALPHACAINE HYDROCHLORIDE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPIVACAINE HYDROCHLORIDE is: 0.25% to 0.5% solution infiltrated locally, up to 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000) per dose; maximum 400 mg per 24 hours. For epidural: 0.5% to 0.75% solution, 15-20 m L for surgical anesthesia.. The standard adult dose of ALPHACAINE HYDROCHLORIDE is: 1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPIVACAINE HYDROCHLORIDE and ALPHACAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPIVACAINE HYDROCHLORIDE is classified as Category C. Bupivacaine is classified as FDA Pregnancy Category C. In first trimester, no well-controlled studies; animal studies have shown potential for fetal toxicity at high doses. Second . ALPHACAINE HYDROCHLORIDE is classified as Category C. Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.